Panacea Venture — Full Portfolio
47 tracked investments · listed companies and verified rows first
BiotechWarrington, US
Mary B. Templeton(Executive Officer)Craig E. Fraser(Executive Officer, Director)Lawrence A. Weinstein(Executive Officer)Kathryn Cole(Executive Officer)John Tattory(Executive Officer)George Cox(Executive Officer)in
Co-investorsAgent Capital
Eos BioInnovation invests in early-stage regenerative medicine therapies and technologies, focusing on cell, gene, and tissue therapies that target disease causes.
BiotechDeep TechDigital HealthHealthtechLongevityMedical DevicesCambridge, US
Brock ReeveJames(Founder and Managing Partner of Panacea Venture)
Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US
Mingxi Li(CEO)inFred Aswad(Chief Scientific Officer)in
Co-investorsSofinnova Ventures
Chime Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end support for biologics production, from cell line development through clinical and commercial manufacturing.
Advanced ManufacturingAI & Machine LearningBiotechSaaSWuhan, CN
Dr. Wei(Board Director and CEO)Jimmy Wei(President)in
Coastar Therapeutics develops gene delivery technologies using erythrocyte-derived membranes to enable genetic medicines for cancer immunotherapy and gene therapies.
BiotechDeep TechHealthtech
Dr. Han LimDr. Luo
Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Ayaan Parikh(CEO)inRahul Vijayan(CTO)inAyaan Parikh Rahul Vijayan(Founder)
Co-investorsGaingelsGravityMaiora Rebel VenturesMK Venture CapitalRebel FundY Combinator+8 more
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investors3B Future Health FundCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalSeventure Partners
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsGV (Google Ventures)OrbiMedOxford Science EnterprisesCowen Healthcare InvestmentsREDMILE
HanchorBio is a biotech company developing innovative immunotherapy drugs for cancer treatment through translational medicine, moving from early research to clinical applications.
BiotechHealthtechMedical DevicesTaiwan, TW
Co-investorsVivo CapitalKorea Investment Partners
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investorsARCH Venture Partners5AM Ventures8VCAtlas VentureTaiho Ventures, LLCTakeda Ventures
Neurochase provides consultancy to biotech and pharmaceutical companies on directly delivering therapies to the central nervous system, drawing on experience with catheter infusions and convection-enhanced delivery.
BiotechHealthtechMedical Devices
Sharon Kanein
Panacea Capital is a venture capital firm, spun out from Kleiner Perkins, that invests in life sciences and healthcare innovation across all geographies.
Biotech
Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions.
BiotechHealthtech
Tactiva Therapeutics develops immuno-oncology treatments using adoptive cell therapy approaches for cancer patients.
BiotechHealthtechMedical DevicesChicago, US
Richard C. Koya(Co-Founder)Kunle Odunsi(Co-Founder)Jay Zhang(CEO)
Co-investorsEFung CapitalVI Partners
XWPharma develops internally discovered small-molecule medicines, focusing on new chemical entities that target time-regulated neurobiology to treat neurological conditions.
Biotech
Co-investorsWI Harper Group
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Affection Animal PharmaceuticalsAffection Animal Pharmaceuticals AapAnimal vaccine R&D companyAnivia Medical HoldingsBase TherapeuticsBioFront TherapeuticsBioGraph 55Eos BioInnovation, LLCFeng BiosciencesFineImmune BiotechnologyGT Apeiron TherapeuticsHarvest Integrated Research Organization (HiRO)Human LongevityInnovative Regenerative MedicineJuventas TherapeuticsKainova TherapeuticsKindstar GlobalLightning BiotherapeuticsManaolana OncologyMirageneMyrtelleNeuInventReal Star RehabilitationSeismic PharmaceuticalsST Phi TherapeuticsTaiLai BiosciencesTriArm TherapeuticsVelaVigoWindtree TherapeuticsXWPharmaZhaoke Ophthalmology
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.









__Twitter.png)























